Hemophilia and Regional Blood Disease Center

Castelfranco Veneto, Italy

Hemophilia and Regional Blood Disease Center

Castelfranco Veneto, Italy
SEARCH FILTERS
Time filter
Source Type

Matino D.,University of Perugia | Gargaro M.,University of Perugia | Santagostino E.,Angelo Bianchi Bonomi Hemophilia and Thrombosis Center | Di Minno M.N.D.,University of Naples Federico II | And 27 more authors.
Journal of Clinical Investigation | Year: 2015

The development of inhibitory antibodies to factor VIII (FVIII) is a major obstacle in using this clotting factor to treat individuals with hemophilia A. Patients with a congenital absence of FVIII do not develop central tolerance to FVIII, and therefore, any control of their FVIII-reactive lymphocytes relies upon peripheral tolerance mechanisms. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulatory enzyme that supports Treg function and peripheral tolerance in adult life. Here, we investigated the association between IDO1 competence and inhibitor status by evaluating hemophilia A patients harboring F8-null mutations that were either inhibitor negative (n=50) or positive (n=50). We analyzed IDO1 induction, expression, and function for any relationship with inhibitor occurrence by multivariable logistic regression and determined that defective TLR9-mediated activation of IDO1 induction is associated with an inhibitor-positive status. Evaluation of experimental hemophilic mouse models with or without functional IDO1 revealed that tryptophan metabolites, which result from IDO1 activity, prevent generation of anti-FVIII antibodies. Moreover, treatment of hemophilic animals with a TLR9 agonist suppressed FVIII-specific B cells by a mechanism that involves IDO1-dependent induction of Tregs. Together, these findings indicate that strategies aimed at improving IDO1 function should be further explored for preventing or eradicating inhibitors to therapeutically administered FVIII protein.

Loading Hemophilia and Regional Blood Disease Center collaborators
Loading Hemophilia and Regional Blood Disease Center collaborators